Trial Profile

Efficacy and safety of probucol plus telmisartan for type-2 diabetic nephropathy: a multicentre, prospective, randomised, double-blind, double-dummy, controlled trial.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 08 Aug 2013

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Probucol (Primary) ; Telmisartan (Primary)
Indications Diabetic nephropathies; Renal failure
Focus Therapeutic Use

Most Recent Events

27 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
16 Oct 2012 Status changed from not yet recruiting to completed as reported by Chinese Clinical Trial Register.
21 May 2012 Planned end date changed from 1 Dec 2011 to 30 Jun 2012 as reported by Chinese Clinical Trial Register.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com